Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, ...

Explore how AI-driven Smart Diagnostics are revolutionizing healthcare, as the market shifts from research to clinical practice. Discover the potential for premium diagnostics, pricing trends, and ...

Covid-19 exposed wide inequities in health in the United States and around the world. But health disparities persisted long before the pandemic. In this article the authors explain why businesses ...